Timing of Novel Drug 1A-116 to Circadian Rhythms Improves Therapeutic Effects against Glioblastoma.
Laura Lucía TrebucqGeorgina Alexandra CardamaPablo Lorenzano MennaDiego Andrés GolombekJuan José ChiesaLuciano MarpeganPublished in: Pharmaceutics (2021)
These results unveil the circadian modulation in the efficacy of 1A-116, likely through RAC1 pathway rhythmicity, suggesting that a chronopharmacological approach is a feasible strategy to improve glioblastoma treatment.